High neutrophil‐to‐lymphocyte ratio as an early sign of cardiotoxicity in breast cancer patients treated with anthracycline
Open Access
- 20 January 2023
- journal article
- research article
- Published by Wiley in Clinical Cardiology
- Vol. 46 (3) , 328-335
Abstract
Background: Cardiotoxicity, defined mainly as left ventricle (LV) dysfunction, is a significant side effect of anthracyclines (ANT) therapy. The need for an early simple marker to identify patients at risk is crucial. A high neutrophil‐to‐lymphocyte ratio (NLR) has been associated with poor prognosis in cancer patients; however, its role as a predictor for cardiotoxicity development is unknown.Objective: Evaluating whether elevated NLR, during ANT exposure, plays a predictive role in the development of cardiotoxicity as defined by LV global longitudinal strain (LV GLS) relative reduction (≥10%).Methods and Results: Data were prospectively collected as part of the Israel Cardio‐Oncology Registry. A total of 74 female patients with breast cancer, scheduled for ANT therapy were included. NLR levels were assessed at baseline (T1) and during ANT therapy (T2). All patients underwent serial echocardiography at baseline (T1) and after the completion of ANT therapy (T3). NLR ≥ 2.58 at T2 was found to be the optimal predictive cutoff for LV GLS deterioration. A relative LV GLS reduction ≥10% was significantly more common among patients with high NLR (50% vs. 20%, p = .009). NLR ≥ 2.58 at T2 increases the risk for LV GLS reduction by fourfold (odds ratio [OR]: 4.63, 95% confidence interval [CI]: 1.29–16.5, p = .02), with each increase of 1‐point NLR adding an additional 15% risk (OR: 1.15, 95% CI: 1.01–1.32, p = .046).Conclusions: Our study provides novel data that high NLR levels, during ANT exposure, have an independent association with the development of LV dysfunction. Routine surveillance of NLR may be an effective means of risk‐stratifying.Keywords
All Related Versions
Funding Information
- Pfizer
This publication has 25 references indexed in Scilit:
- Higher Neutrophil/Lymphocyte Ratio Is Related to Lower Ejection Fraction and Higher Long-term All-Cause Mortality in ST-Elevation Myocardial Infarction PatientsCanadian Journal of Cardiology, 2014
- Use of Myocardial Strain Imaging by Echocardiography for the Early Detection of Cardiotoxicity in Patients During and After Cancer ChemotherapyJACC, 2014
- Prognostic value of neutrophil/lymphocyte ratio in patients with ST-elevated myocardial infarction undergoing primary coronary intervention: A prospective, multicenter studyInternational Journal of Cardiology, 2013
- Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012European Journal of Cancer, 2013
- Changes in Left Ventricular Longitudinal Strain with Anthracycline Chemotherapy in Adolescents Precede Subsequent Decreased Left Ventricular Ejection FractionJournal of the American Society of Echocardiography, 2012
- Cancer treatment and survivorship statistics, 2012CA: A Cancer Journal for Clinicians, 2012
- Blood Neutrophil-to-Lymphocyte Ratio Predicts Survival in Patients with Colorectal Liver Metastases Treated with Systemic ChemotherapyAnnals of Surgical Oncology, 2009
- Identification of Anthracycline Cardiotoxicity: Left Ventricular Ejection Fraction Is Not EnoughJournal of the American Society of Echocardiography, 2008
- The Potential Role of Neutrophils in Promoting the Metastatic Phenotype of Tumors Releasing Interleukin-8Clinical Cancer Research, 2004
- Activated human neutrophils release hepatocyte growth factor/scatter factorEuropean Journal of Surgical Oncology, 2001